Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
Martin T, Mikhael J, Hajek R, Kim K, Suzuki K, Hulin C, Garg M, Quach H, Sia H, George A, Konstantinova T, Risse ML, Asset G, Macé S, van de Velde H, Moreau P.
Martin T, et al. Among authors: asset g.
Blood Adv. 2022 Aug 9;6(15):4506-4515. doi: 10.1182/bloodadvances.2021006713.
Blood Adv. 2022.
PMID: 35594559
Free PMC article.
Clinical Trial.